Barinthus Biotherapeutics (BRNS) Goodwill & Intangibles (2021 - 2026)

Barinthus Biotherapeutics (BRNS) has 6 years of Goodwill & Intangibles data on file, last reported at $13.7 million in Q1 2026.

• Quarterly Goodwill & Intangibles fell 35.4% year-over-year to $13.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.7 million (down 35.4% YoY) and the FY2025 annual result came in at $14.3 million, down 34.9% from the prior year.
• Goodwill & Intangibles fell to $13.7 million in Q1 2026, from $14.3 million in the prior quarter.
• In the past five years, Goodwill & Intangibles ranged from a high of $43.3 million in Q1 2022 to a low of $13.7 million in Q1 2026.
• A 5-year average of $31.5 million and a median of $36.5 million in 2024 frame the typical range for Goodwill & Intangibles.
• Annual changes were most pronounced in 2023 — Goodwill & Intangibles decreased 7.81% — and 2025, when it sank 57.34%.
• Tracing BRNS's Goodwill & Intangibles over 5 years: stood at $40.5 million in 2022, then declined by 7.81% to $37.3 million in 2023, then sank by 41.19% to $21.9 million in 2024, then sank by 34.9% to $14.3 million in 2025, then retreated by 4.35% to $13.7 million in 2026.
• The last three Goodwill & Intangibles figures came in at $13.7 million (Q1 2026), $14.3 million (Q4 2025), and $14.9 million (Q3 2025), per Business Quant data.